Janmejay Singh
Overview
Explore the profile of Janmejay Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmad S, Singh A, Bano N, Raza K, Singh J, Medigeshi G, et al.
Int J Biol Macromol
. 2024 May;
270(Pt 2):132332.
PMID: 38768914
Two of the deadliest infectious diseases, COVID-19 and tuberculosis (TB), have combined to establish a worldwide pandemic, wreaking havoc on economies and claiming countless lives. The optimised, multitargeted medications may...
2.
Singh J, Anantharaj A, Kumar P, Pandey R, Pandey A, Medigeshi G
J Interferon Cytokine Res
. 2024 Apr;
44(7):325-333.
PMID: 38557204
India saw a spike in COVID-19 cases in early 2023, and this wave of infection was attributed to XBB sublineages of SARS-CoV-2 Omicron variant. The impact of XBB wave was...
3.
Rizvi Z, Dandotiya J, Sadhu S, Khatri R, Singh J, Singh V, et al.
Commun Biol
. 2023 Sep;
6(1):935.
PMID: 37704701
A recently emerged sub-lineage of Omicron, BA.5, together with BA.4, caused a fifth wave of coronavirus disease (COVID-19) in South Africa and subsequently emerged as a predominant strain globally due...
4.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Suneetha P, et al.
Hum Vaccin Immunother
. 2023 Apr;
19(1):2203632.
PMID: 37113012
Optimum formulation of Biological-E's protein subunit CORBEVAX™ vaccine was selected in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. This is a phase-3...
5.
Deshpande S, Ansari M, Sutar J, Das P, Hingankar N, Mukherjee S, et al.
Microbiol Spectr
. 2023 Mar;
:e0433222.
PMID: 36946746
Understanding the quality of immune repertoire triggered during natural infection can provide vital clues that form the basis for development of a humoral immune response in some individuals capable of...
6.
Singh J, Anantharaj A, Panwar A, Rani C, Bhardwaj M, Kumar P, et al.
PLoS Pathog
. 2023 Feb;
19(2):e1011196.
PMID: 36827451
The Omicron variant of SARS-CoV-2 is capable of infecting unvaccinated, vaccinated and previously-infected individuals due to its ability to evade neutralization by antibodies. With multiple sub-lineages of Omicron emerging in...
7.
Parray H, Narayanan N, Garg S, Rizvi Z, Shrivastava T, Kushwaha S, et al.
PLoS Pathog
. 2022 Dec;
18(12):e1010994.
PMID: 36508467
The emergence of new variants of SARS-CoV-2 necessitates unremitting efforts to discover novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb named P4A2 that can neutralize all...
8.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Reddy Mogulla R, Suneetha P, et al.
Vaccine
. 2022 Nov;
40(49):7130-7140.
PMID: 36328879
Background: After establishing safety and immunogenicity of Biological-E's CORBEVAX™ vaccine in adult population (18-80 years) in Phase 1-3 studies, vaccine is further tested in children and adolescents in this study....
9.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Turaga K, et al.
EBioMedicine
. 2022 Aug;
83:104217.
PMID: 35970020
Background: We assessed the efficacy of a receptor-binding domain (RBD)-based protein subunit COVID-19 vaccine. Methods: A randomised Phase-1/2 trial followed by a Phase-2 trial were conducted to assess the safety...
10.
Das S, Singh J, Shaman H, Singh B, Anantharaj A, Sharanabasava P, et al.
Nat Commun
. 2022 Jun;
13(1):3451.
PMID: 35705548
Many adults in India have received at least one dose of COVID-19 vaccine with or without a prior history SARS-CoV-2 infection. However, there is limited information on the effect of...